Research article
B lymphocyte-typing for prediction of clinical response to rituximab
1 Department of Internal Medicine, Division of Rheumatology and Immunology, Medical University Graz, Auenbruggerplatz 15, Graz, A-8036, Austria
2 Internal Medicine, Hospital Barmherzige Brueder, Bergstrasse 27, Graz-Eggenberg, A-8020, Austria
Arthritis Research & Therapy 2012, 14:R161 doi:10.1186/ar3901
Published: 6 July 2012Additional files
Additional file 1:
Figure S1 Gating strategy. Mononuclear cells were incubated in 4 separate tubes containing the following monoclonal antibodies: a) Isotypen-specific control antibodies; b) IgD-FITC, CD27-APC, CD38-PE/Cy7, CD45-APC/H7, CD19-HorizonBlue, CD24-PE, CD3-/CD14-PerCP; c) IgD-FITC, CD27-APC, CD38-PE/Cy7, CD45-APC/H7, CD19-HorizonBlue, CD80-PE, CD3-/CD14-PerCP; d) IgD-FITC, CD27-APC, CD38-PE/Cy7, CD45-APC/H7, CD19-HorizonBlue, CD95-PE, CD3-/CD14-PerCP. CD45 positive leukocytes were gated and after eliminating PerCP positive T cells and monocytes, B cells were separated according to their CD27 and IgD expression. Thereafter the expression of CD38, CD80 or CD95 was analyzed in each B cell population.
Format: PPT Size: 704KB Download file
This file can be viewed with: Microsoft PowerPoint Viewer
Additional file 2:
Figure S2 Effect of the time of preparation on the number of day 15 B cells in RA patients with good/moderate or no EULAR response.
Format: PPT Size: 291KB Download file
This file can be viewed with: Microsoft PowerPoint Viewer
Additional file 3:
Figure S3 Frequency of CD95+ cells in the naïve, post-switch and double negative B cell subset.
Format: PPT Size: 321KB Download file
This file can be viewed with: Microsoft PowerPoint Viewer
